A CLINICAL EXAMINATION OF THE EFFICACY OF PREPARATION OF
DR MICHAELS® (ALSO BRANDED AS SORATINEX®) PRODUCTS IN THE
TREATMENT OF PSORIASIS

J. HERCOGOVÁ1,2, M. FIORANELLI3, S. GIANFALDONI4, A.A. CHOKOLOVA5,6,
G. TCHERNEV7, U. WOLLINA8, M. TIRANT9, F. NOVOTNY10, M.G. ROCCIA11, G.K.
MAXIMOV12, K. FRANÇA13,14 and T. LOTTI15

12nd Medical Faculty, Charles University, Bulovka Hospital, 3Institute of Clinical and Experimental Medicine,
Prague, Czech Republic; 4Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University,
Rome, Italy; 5Dermatological Department University of Pisa, Pisa, Italy; 6"Onkoderma" - Polyclinic for
dermatology and dermatologic surgery, Sofia, Bulgaria; 7Department of Dermatology and Venereology,
Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria; 8Medical Institute of Ministry of Interior
(MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria; 9Department
of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany;
10Psoriasis & Skin Clinic, Melbourne, Australia. 11PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská
Prague 1, Czech Republic; 12University B.I.S. Group of Institutions, Punjab Technical University, Punjab,
India; 13Department “Medicinal Information and Non-interventional studies”, Bulgarian Drug Agency;
Sofia, Bulgaria; 14Department of Dermatology & Cutaneous Surgery, Department of Psychiatry & Behavioral
Sciences, Institute for Bioethics & Health Policy, University of Miami, Miller School of Medicine, Miami, FL,
USA; 15Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi “G. Marconi”-
Rome, Italy; 16Chair of Dermatology, University of Rome “G. Marconi” Rome, Italy

Psoriasis is a chronic inflammatory disease with negative impacts both physically and psychologically. It is a
common disorder affecting 2-3% of the total world population, in some cases causing changes to the nails and joints
as well as skin lesions. The cutaneous manifestations of psoriasis can vary in morphology and severity and therapy
should be tailored accordingly. The aim of the study was to investigate the efficacy of Dr Michaels® (Soratinex®)
product line in the treatment of psoriatic patients with different age and disease severity. A total number of 270
patients with verified psoriasis, aged 9-60 years old participated in the studies, including 128 children: 23 girls and
105 boys, (all of them selected from the Department of Dermato-allergology of the Russian Pediatric Hospital Clinic,
Moscow, and of the 4th Department of Dermatology of the 52nd Moscow City Hospital Clinic). The patients were
separated into 3 groups according to the severity of the disease (based on the PASI-index). All the patients have been
treated with Dr Michaels® (Soratinex®) products twice daily, as three different forms were available for application:
a cleansing gel, an ointment and a conditioner. The severity of the disease and the efficacy of the treatment have been
defined with the evaluation of the PASI index of each patient. The obtained results were recorded in a graphic form
showing the changes of the PASI-index on days 3, 7, 14, and 21 counted from the start of the trial. Clinical remission
was achieved in 147 patients, a significant improvement in 73, partial improvement in 32, while no effect was seen
in 12 patients and deterioration in 6. This open trial demonstrated the clinical efficacy of topical application of Dr
Michaels® (Soratinex®) preparation. We observed clinical remissions of psoriasis in adults and in children.